ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · EFO_0006865

urgency urinary incontinence

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. urgency urinary incontinence. Diseases, record EFO_0006865. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0006865

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
urgency urinary incontinence
Open Targets
Open Targets ID
EFO_0006865
Open Targets
Other names
urinary incontinence, urge
Open Targets
MeSH
D053202
MeSH
Highest stage of its drugs
Approval, for 10 of its 20 drugs, from DailyMed and EMA Human Drugs
Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
MIRABEGRONCHEMBL2095212Small moleculeApprovalDailyMed766Drugs and targets
BOTULINUM TOXIN TYPE ACHEMBL4297862ProteinApprovalDailyMed652Drugs and targets
OXYBUTYNINCHEMBL1231Small moleculeApprovalDailyMed and EMA Human Drugs1044Drugs and targets
OXYBUTYNIN CHLORIDECHEMBL1133Small moleculeApprovalDailyMed522Drugs and targets
TROSPIUM CHLORIDECHEMBL3084748Small moleculeApprovalDailyMed322Drugs and targets
VIBEGRONCHEMBL2107826Small moleculeApprovalDailyMed322Drugs and targets
SOLIFENACIN SUCCINATECHEMBL1200803Small moleculeApprovalDailyMed400Drugs and targets
DARIFENACIN HYDROBROMIDECHEMBL1200935Small moleculeApprovalDailyMed and EMA Human Drugs300Drugs and targets
FESOTERODINE FUMARATECHEMBL1201765Small moleculeApprovalDailyMed200Drugs and targets
TOLTERODINE TARTRATECHEMBL1722209Small moleculeApprovalDailyMed200Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
CHRM2Muscarinic acetylcholine receptor M210Muscarinic acetylcholine receptor M2 antagonistApprovalhttps://conductscience.org/library/genes/1129Drugs and targets
CHRM3Muscarinic acetylcholine receptor M310Muscarinic acetylcholine receptor M3 antagonistApprovalhttps://conductscience.org/library/genes/1131Drugs and targets
SNAP25Synaptosomal-associated protein 254Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitorApprovalhttps://conductscience.org/library/genes/6616Drugs and targets
ADRB3Beta-3 adrenergic receptor2Beta-3 adrenergic receptor agonistApprovalhttps://conductscience.org/library/genes/155Drugs and targets
ESR1Estrogen receptor1Estrogen receptor modulatorPhase 3https://conductscience.org/library/genes/2099Drugs and targets
ESR2Estrogen receptor1Estrogen receptor modulatorPhase 3https://conductscience.org/library/genes/2100Drugs and targets
TACR1Substance-P receptor1Neurokinin 1 receptor antagonistPhase 2https://conductscience.org/library/genes/6869Drugs and targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01089751Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) DailyPhase 43222013-09-26Overactive BladderTROSPIUM CHLORIDEOpen Targets' reading of its recordClinicalTrials.gov
NCT01829425Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or PharmacotherapyNot applicable1652019-04-01Urinary Incontinence, UrgeOXYBUTYNIN, TOLTERODINEIts record names the diseaseClinicalTrials.gov
NCT04171531Sling vs Botox for Mixed IncontinencePhase 31502025-03-20Urinary Incontinence, Stress, Urinary Incontinence, UrgeONABOTULINUMTOXINAIts record names the diseaseClinicalTrials.gov
NCT02495389Mirabegron and Urinary Urgency IncontinencePhase 4842020-11-13Overactive BladderMIRABEGRONOpen Targets' reading of its recordClinicalTrials.gov
NCT02176642Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.Phase 4552018-01-23Urinary Urge IncontinenceOXYBUTYNINIts record names the diseaseClinicalTrials.gov
NCT04907032Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)Phase 4542023-07-20Overactive BladderMIRABEGRONIts record names the diseaseClinicalTrials.gov
NCT00345332A Multi-Center Trial of Botox for Severe Urge Urinary IncontinenceNot applicable312017-07-11Urinary IncontinenceBOTULINUM TOXIN TYPE AOpen Targets' reading of its recordClinicalTrials.gov
NCT02436889Treatment of Incontinence Without Memory ProblemsPhase 4232019-04-16Urge Incontinence, Urinary Incontinence, UrgeMIRABEGRONIts record names the diseaseClinicalTrials.gov
NCT01226706Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge IncontinenceNot applicable212017-07-03Urinary Urge IncontinenceBOTULINUM TOXIN TYPE A, ONABOTULINUMTOXINAOpen Targets' reading of its recordClinicalTrials.gov
NCT05067478Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)403Overactive BladderVIBEGRONOpen Targets' reading of its recordClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Sanctura XR® vs Placebo: serious adverse events2 of 1623 of 158320NCT01089751Trial comparisons
Hypnotherapy vs Anticholinergic Medications: deaths from any cause0 of 700 of 72142NCT01829425Trial comparisons
Hypnotherapy vs Anticholinergic Medications: serious adverse events1 of 703 of 72142NCT01829425Trial comparisons
Botox A vs Mid-Urethral Sling: deaths from any cause0 of 710 of 69140NCT04171531Trial comparisons
Botox A vs Mid-Urethral Sling: serious adverse events3 of 718 of 69140NCT04171531Trial comparisons
Posterior Tibial Nerve Stimulation With Mirabegron vs Posterior Tibial Nerve Stimulation Plus Placebo: deaths from any cause0 of 270 of 2754NCT04907032Trial comparisons
Posterior Tibial Nerve Stimulation With Mirabegron vs Posterior Tibial Nerve Stimulation Plus Placebo: serious adverse events0 of 270 of 2754NCT04907032Trial comparisons
Oxybutynin Plus PTNS vs Placebo Plus PTNS: deaths from any cause0 of 180 of 1634NCT02176642Trial comparisons
Oxybutynin Plus PTNS vs Placebo Plus PTNS: serious adverse events0 of 180 of 1634NCT02176642Trial comparisons
Botox Group vs Placebo Group: serious adverse events0 of 200 of 1131NCT00345332Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials17

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
15538257RESULT1PubMed
40323617DERIVED1PubMed
40176006DERIVED1PubMed
39101958DERIVED1PubMed
38212101DERIVED1PubMed
38178267DERIVED1PubMed
37160401DERIVED2PubMed
37095473DERIVED1PubMed
35881009DERIVED1PubMed
35412069DERIVED1PubMed

1 to 10 of 17

See all 17 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0006865

GET https://conductscience.org/api/diseases/v1/EFO_0006865/trials?page=2

API referenceFor AI assistants